Vilnius, Lithuania; February 14, 2023:
Droplet Genomics, an emerging innovator and provider of microfluidic and single cell analysis technologies, announced today the appointment of Andy Watson as its Chairman of the Board of Directors.
“We are delighted to welcome Andy as our new Board Chair,” said Juozas Nainys, CEO of Droplet Genomics. “His extensive experience and proven track record in the genomics industry will be invaluable as we continue to grow and expand.”
With over 25 years of experience in the genomics industry, Watson brings a wealth of knowledge and expertise. He has held senior corporate and commercial leadership positions at small and large companies, including Applied Biosystems (now Thermo Fisher Scientific), Raindance Technologies (now Bio-Rad), and Cell Signaling Technology. His expertise in business strategy, fundraising and operations, coupled with his passion for innovation and commitment to driving growth, make him a valuable addition.
“I am honored to join Droplet Genomics and work alongside such a talented and dedicated team,” said Watson. “I’ve been impressed to see that the company’s current products are already being utilized successfully by leading single-cell research and discovery organizations worldwide. Furthermore, the company’s new micro-capsule technology is generating a powerful pipeline of products and applications that will disrupt the entire single-cell analysis market. I am excited to help the company enter this new phase of commercial growth and technology adoption.”
About Droplet Genomics: Droplet Genomics is an emerging developer and provider of innovative microfluidic solutions for the life sciences. Its novel technology platform enables new insights into the biology of single cells, with immediate applications in research and bio-molecular discovery. Droplet Genomics’ systems are installed in over 50 leading academic and commercial laboratories globally with a rapid growth trajectory.